iTeos Therapeutics, Inc. (NASDAQ:ITOS) was the recipient of a large growth in short interest in the month of March. As of March 31st, there was short interest totalling 1,320,000 shares, a growth of 128.4% from the March 15th total of 578,000 shares. Based on an average trading volume of 282,200 shares, the short-interest ratio is presently 4.7 days. Currently, 4.5% of the company’s shares are sold short.
NASDAQ:ITOS opened at $23.99 on Thursday. iTeos Therapeutics has a twelve month low of $17.50 and a twelve month high of $47.61. The stock’s 50 day moving average price is $35.75 and its two-hundred day moving average price is $31.12.
iTeos Therapeutics (NASDAQ:ITOS) last released its earnings results on Tuesday, March 23rd. The company reported ($0.43) earnings per share for the quarter, meeting the consensus estimate of ($0.43). Research analysts forecast that iTeos Therapeutics will post -2.72 EPS for the current fiscal year.
In related news, major shareholder Bioventures 2014 L.P. Mpm sold 5,783 shares of the stock in a transaction that occurred on Wednesday, April 7th. The shares were sold at an average price of $32.55, for a total value of $188,236.65. The sale was disclosed in a filing with the SEC, which can be accessed through this link.
Several institutional investors have recently added to or reduced their stakes in the company. Penserra Capital Management LLC acquired a new stake in iTeos Therapeutics in the 4th quarter valued at about $27,000. Morgan Stanley acquired a new stake in shares of iTeos Therapeutics in the third quarter valued at approximately $59,000. Strs Ohio bought a new position in shares of iTeos Therapeutics during the 3rd quarter worth approximately $66,000. JPMorgan Chase & Co. acquired a new position in shares of iTeos Therapeutics during the 3rd quarter worth approximately $96,000. Finally, Citigroup Inc. raised its stake in iTeos Therapeutics by 544.1% in the 4th quarter. Citigroup Inc. now owns 3,304 shares of the company’s stock valued at $112,000 after acquiring an additional 2,791 shares during the period. Institutional investors own 71.07% of the company’s stock.
iTeos Therapeutics Company Profile
Iteos Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for cancer patients. Its product pipeline includes EOS-850, a small molecule antagonist of the adenosine A2a receptor that is an open-label Phase 1/2a clinical trial in adult patients; and EOS-448, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1/2a clinical trial.
See Also: Gap Up Stocks
Receive News & Ratings for iTeos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iTeos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.